Literature DB >> 16511505

Statins: another class of antihypertensive agents?

H J Milionis1, E N Liberopoulos, A Achimastos, M S Elisaf, D P Mikhailidis.   

Abstract

The assessment of global cardiovascular risk is an essential step in the management of atherosclerotic disease prevention. Among the risk factors to be addressed are hypertension and hyperlipidaemia; these commonly coexist. A neutral or lipid-friendly antihypertensive agent is probably useful in the presence of lipid abnormalities. Similarly, statins have been shown to decrease cardiovascular risk in hypertensive patients. There is also experimental and clinical evidence that statins have blood pressure (BP)-lowering effects. In this review, we discuss the beneficial effects of statins on BP, and provide an overview of the underlying pathophysiology. We also consider the evidence justifying the use of statins in the management of hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511505     DOI: 10.1038/sj.jhh.1002001

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  13 in total

Review 1.  Statins as adjunctive therapy in the management of hypertension.

Authors:  Joshua Liao; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

2.  Use of statins and blood pressure.

Authors:  Dana E King; Arch G Mainous; Brent M Egan; Marty Player; Mark E Geesey
Journal:  Am J Hypertens       Date:  2007-09       Impact factor: 2.689

3.  Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.

Authors:  Chengyun Liu; Jingjing Wan; Qunfang Yang; Benling Qi; Wen Peng; Xuelin Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

Review 4.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

Review 5.  Treatment of dyslipidemia in patients with type 2 diabetes.

Authors:  Krishnaswami Vijayaraghavan
Journal:  Lipids Health Dis       Date:  2010-12-20       Impact factor: 3.876

6.  Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study.

Authors:  Anastazia Kei; Moses Elisaf; Elisavet Moutzouri; Stavroula Tsiara; Evangelos Liberopoulos
Journal:  Int J Hypertens       Date:  2011-05-15       Impact factor: 2.420

7.  Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats.

Authors:  Jacek Owczarek; Magdalena Jasińska-Stroschein; Daria Orszulak-Michalak
Journal:  ScientificWorldJournal       Date:  2012-05-03

8.  Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.

Authors:  Elijah Saunders; Greg Cable; Joel Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

9.  CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults.

Authors:  Amber L Beitelshees; Christina L Aquilante; Hooman Allayee; Taimour Y Langaee; Gregory J Welder; Richard S Schofield; Issam Zineh
Journal:  Hum Genomics       Date:  2012-08-02       Impact factor: 4.639

Review 10.  Analysis of antihypertensive effects of statins.

Authors:  Haralampos J Milionis; Evagelos N Liberopoulos; Moses S Elisaf; Dimitri P Mikhailidis
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.